home / stock / tlsa / tlsa quote
Last: | $0.728 |
---|---|
Change Percent: | 5.65% |
Open: | $0.77 |
Close: | $0.728 |
High: | $0.8427 |
Low: | $0.7 |
Volume: | 284,845 |
Last Trade Date Time: | 06/13/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.728 | $0.77 | $0.728 | $0.8427 | $0.7 | 284,845 | 06-13-2024 |
$0.8161 | $0.92 | $0.8161 | $0.9498 | $0.7715 | 316,469 | 06-12-2024 |
$0.99 | $0.94 | $0.99 | $1.025 | $0.86 | 510,835 | 06-11-2024 |
$0.9999 | $1 | $0.9999 | $1 | $0.9177 | 455,315 | 06-10-2024 |
$1 | $1 | $1 | $1.03 | $0.9506 | 257,488 | 06-07-2024 |
$1 | $1.03 | $1 | $1.05 | $0.91 | 614,131 | 06-06-2024 |
$1.01 | $1.02 | $1.01 | $1.05 | $0.98 | 397,288 | 06-05-2024 |
$1 | $1 | $1 | $1.01 | $0.9576 | 207,415 | 06-04-2024 |
$1 | $1.04 | $1 | $1.05 | $0.9 | 248,482 | 06-03-2024 |
$0.9999 | $0.94 | $0.9999 | $1.04 | $0.94 | 516,793 | 05-31-2024 |
$0.94 | $0.93 | $0.94 | $0.95 | $0.9 | 97,128 | 05-30-2024 |
$0.9374 | $0.92 | $0.9374 | $0.94 | $0.8702 | 137,972 | 05-29-2024 |
$0.919 | $0.89 | $0.919 | $0.9263 | $0.8305 | 301,464 | 05-28-2024 |
$0.8099 | $0.8 | $0.8099 | $0.8099 | $0.7403 | 84,265 | 05-27-2024 |
$0.8099 | $0.8 | $0.8099 | $0.8099 | $0.7403 | 84,265 | 05-24-2024 |
$0.7407 | $0.781 | $0.7407 | $0.82 | $0.7403 | 76,129 | 05-23-2024 |
$0.81 | $0.82 | $0.81 | $0.83 | $0.79 | 108,719 | 05-22-2024 |
$0.82 | $0.79 | $0.82 | $0.83 | $0.758 | 120,805 | 05-21-2024 |
$0.77 | $0.81 | $0.77 | $0.811 | $0.7342 | 188,930 | 05-20-2024 |
$0.744 | $0.722 | $0.744 | $0.76 | $0.671 | 109,991 | 05-17-2024 |
News, Short Squeeze, Breakout and More Instantly...
Tiziana Life Sciences plc Company Name:
TLSA Stock Symbol:
NASDAQ Market:
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has received acceptance...
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months. FDA Allowance for an additional 20 Patients to be enrolled in the intranasal foralumab Multiple S...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ant...